The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.
The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix stimulating cellular colonization and integration with the surrounding tissue.
CorNeat EverPatch Advantages
Inert and non-degradable material – reduces complications Vs current degradable solutions
Ease of handling
Extremely easy to handle and suture. Elastic and durable (cannot be torn by the sutures)
Cannot carry or transmit disease
Reduces operating time and eye bank costs. Eliminates complexities related to the transportation and storage of biological materials
Translucent when wet – hardly visible when implanted subconjunctivly
Covering irritating implants such as in Glaucoma tube shunts or exposed sutures, displacing the need for preserved tissue/collagen.
Covering tissue gaps/weaknesses, resulting either from traumatic, disease related or iatrogenic damage.
Clinical trials for the CorNeat EverPatch are planned to start in Q3 2019, with sites planned in Canada and Israel. The trials are geared toward obtaining a CE Mark in 2020. CorNeat Vision plans to extend the solution to the US market as a second step and work toward FDA approval. The exact FDA path will be coordinated with the authorities late 2019.